Skip to main content
Clinical Trials/NCT06774950
NCT06774950
Not yet recruiting
Not Applicable

Améliorer La Prise En Soins Et La Qualité De Vie Des Patients Diabétiques De Type 2 (Alliance DT2)

Réseau de soins Delta0 sites154 target enrollmentStarted: March 1, 2025Last updated:

Overview

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Réseau de soins Delta
Enrollment
154
Primary Endpoint
Glycated haemoglobin HbA1c (∆HbA1c)

Overview

Brief Summary

The aim of this study is to obtain a better glycemic index score (decrease) by improving the care and quality of life of type 2 diabetic patients for a possible remission of diabetes.

This will be achieved through an intervention that includes a strategy for training primary care physicians and other healthcare professionals in patient therapeutic education (TPE), as well as group and/or individual TPE-related activities/tools made available to patients, funded and encouraged for individualized planning. Intervention follow-up will be carried out by means of quality-of-life questionnaires for patients who have undergone the new method, compared with patients who have received the usual care.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Supportive Care
Masking
Double (Participant, Care Provider)

Eligibility Criteria

Ages
40 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients with newly diagnosed type 2 diabetes (less than 10 years)
  • Age (between 40 and 65)

Exclusion Criteria

  • Significant comorbidities linked to worsening diabetes (such as renal failure, previous myocardial infarction, retinopathy, signs or symptoms of severe diabetic neuropathy or diabetic foot ulcers), severe osteoarthritis or as judged by the attending physician.
  • Pregnant or breast-feeding women
  • Persons who are unable to give signed informed consent

Outcomes

Primary Outcomes

Glycated haemoglobin HbA1c (∆HbA1c)

Time Frame: During 18 month

Mean change in glycated haemoglobin HbA1c (∆HbA1c)

Secondary Outcomes

  • Health-related quality of life (∆ EQ-5D-5L)(During 18 months)
  • Cost-effectiveness analysis(At 12 and 18 months)
  • Diabetes self-care behaviours measured by the Diabetes Intention, Attitude, and Behavior Questionnaire (∆ DIAB-Q)(During 18 months)
  • Fat/lean body mass (∆ body composition)(During 18 months)

Investigators

Sponsor
Réseau de soins Delta
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Minette-Joëlle Zeukeng

Principal Investigator

Réseau de soins Delta

Similar Trials